Key Findings:US hotel RevPAR growth has been flat QTD through November, improving from -1% Y/Y in 3Q, but stable with 2Q. Specifically, RevPAR grew +1% Y/Y MTD in November, accelerating from -1% Y/Y in October.International RevPAR growth has improved to the high-single-digit range QTD, from low- to
Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
Post-results, we think the disconnect between fundamentals and investor sentiment offers attractive upside for the highest-quality names in our coverage. We’ve become more constructive on the companies below:META (Outperform) - We are adding Meta Platforms to the Best Ideas List and maintain our $9
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. ...
Figure 1. 3Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 3Q results and provided a healthy outlook for 4Q. Nights and Experiences booked growth in 3Q of +8.8% Y/Y was ~150bps above Street estimates. Revenue was in line with expectations, while adj. E
Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.